Jost Klawitter
Concepts (393)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dronabinol | 22 | 2025 | 226 | 3.110 |
Why?
| | Tandem Mass Spectrometry | 16 | 2024 | 532 | 3.040 |
Why?
| | Cannabinoids | 12 | 2024 | 161 | 3.010 |
Why?
| | Cannabidiol | 14 | 2025 | 119 | 2.900 |
Why?
| | Endocannabinoids | 6 | 2025 | 63 | 2.650 |
Why?
| | Cannabis | 20 | 2025 | 487 | 2.190 |
Why?
| | Chromatography, High Pressure Liquid | 12 | 2024 | 597 | 2.130 |
Why?
| | Immunosuppressive Agents | 14 | 2019 | 889 | 1.820 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 7 | 2022 | 260 | 1.700 |
Why?
| | Kidney | 18 | 2022 | 1467 | 1.630 |
Why?
| | Sirolimus | 8 | 2019 | 275 | 1.470 |
Why?
| | Mass Spectrometry | 8 | 2021 | 738 | 1.430 |
Why?
| | Cyclosporine | 8 | 2019 | 268 | 1.360 |
Why?
| | Metabolomics | 13 | 2022 | 678 | 1.340 |
Why?
| | Limit of Detection | 9 | 2024 | 85 | 1.280 |
Why?
| | Hallucinogens | 8 | 2024 | 104 | 1.210 |
Why?
| | Chromatography, Liquid | 9 | 2024 | 433 | 1.200 |
Why?
| | Secologanin Tryptamine Alkaloids | 1 | 2024 | 4 | 0.930 |
Why?
| | Oxylipins | 1 | 2025 | 40 | 0.920 |
Why?
| | Mitragyna | 1 | 2024 | 5 | 0.920 |
Why?
| | Alkaloids | 1 | 2024 | 30 | 0.910 |
Why?
| | Diphosphonates | 1 | 2025 | 66 | 0.890 |
Why?
| | Proteomics | 11 | 2020 | 1109 | 0.890 |
Why?
| | Glycerides | 1 | 2024 | 21 | 0.860 |
Why?
| | Proteome | 3 | 2016 | 472 | 0.850 |
Why?
| | Arachidonic Acids | 1 | 2024 | 62 | 0.840 |
Why?
| | Deoxycytidine | 1 | 2025 | 179 | 0.840 |
Why?
| | Kidney Transplantation | 11 | 2018 | 701 | 0.820 |
Why?
| | Analgesia | 1 | 2024 | 94 | 0.800 |
Why?
| | Metabolome | 5 | 2022 | 350 | 0.640 |
Why?
| | Inflammation | 5 | 2025 | 2834 | 0.640 |
Why?
| | Pain | 1 | 2025 | 754 | 0.640 |
Why?
| | Milk, Human | 1 | 2021 | 158 | 0.640 |
Why?
| | Plant Extracts | 5 | 2024 | 202 | 0.610 |
Why?
| | Biomarkers | 13 | 2021 | 4143 | 0.600 |
Why?
| | Graft Rejection | 6 | 2018 | 620 | 0.570 |
Why?
| | Everolimus | 2 | 2015 | 91 | 0.560 |
Why?
| | Urine | 1 | 2017 | 56 | 0.550 |
Why?
| | Reproducibility of Results | 9 | 2024 | 3264 | 0.540 |
Why?
| | Isoprostanes | 3 | 2012 | 15 | 0.530 |
Why?
| | Glomerular Filtration Rate | 7 | 2022 | 745 | 0.530 |
Why?
| | Energy Metabolism | 8 | 2022 | 919 | 0.500 |
Why?
| | Arthritis, Rheumatoid | 1 | 2025 | 1167 | 0.500 |
Why?
| | Plasma | 1 | 2017 | 212 | 0.490 |
Why?
| | Mitochondria | 4 | 2017 | 946 | 0.460 |
Why?
| | Oxidative Stress | 10 | 2019 | 1314 | 0.450 |
Why?
| | Mycophenolic Acid | 2 | 2014 | 117 | 0.450 |
Why?
| | Medical Marijuana | 3 | 2021 | 117 | 0.450 |
Why?
| | Rats | 14 | 2024 | 5639 | 0.440 |
Why?
| | Marijuana Smoking | 4 | 2021 | 249 | 0.440 |
Why?
| | Humans | 60 | 2025 | 136764 | 0.440 |
Why?
| | Lovastatin | 2 | 2013 | 37 | 0.430 |
Why?
| | TOR Serine-Threonine Kinases | 2 | 2015 | 412 | 0.430 |
Why?
| | Multiprotein Complexes | 1 | 2015 | 163 | 0.420 |
Why?
| | Prenatal Exposure Delayed Effects | 3 | 2025 | 605 | 0.420 |
Why?
| | Glucuronides | 2 | 2022 | 18 | 0.410 |
Why?
| | S-Adenosylhomocysteine | 1 | 2013 | 24 | 0.410 |
Why?
| | S-Adenosylmethionine | 1 | 2013 | 54 | 0.400 |
Why?
| | Male | 45 | 2025 | 67309 | 0.380 |
Why?
| | Tacrolimus | 3 | 2018 | 199 | 0.360 |
Why?
| | Fatty Acids | 1 | 2014 | 442 | 0.360 |
Why?
| | Artifacts | 1 | 2011 | 129 | 0.340 |
Why?
| | Animals | 29 | 2025 | 36823 | 0.340 |
Why?
| | Flowers | 2 | 2021 | 64 | 0.330 |
Why?
| | Neurons | 2 | 2019 | 1587 | 0.330 |
Why?
| | Atmospheric Pressure | 2 | 2021 | 23 | 0.320 |
Why?
| | Proteinuria | 1 | 2010 | 97 | 0.320 |
Why?
| | Female | 37 | 2025 | 72787 | 0.320 |
Why?
| | Proto-Oncogene Proteins c-akt | 3 | 2017 | 437 | 0.310 |
Why?
| | Signal Transduction | 7 | 2017 | 5075 | 0.300 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 2 | 2019 | 180 | 0.290 |
Why?
| | Kidney Medulla | 1 | 2008 | 35 | 0.290 |
Why?
| | Kidney Tubules, Collecting | 1 | 2008 | 31 | 0.290 |
Why?
| | Enzymes | 1 | 2008 | 67 | 0.280 |
Why?
| | Parkinson Disease | 2 | 2024 | 490 | 0.280 |
Why?
| | Cyclophilins | 2 | 2017 | 40 | 0.270 |
Why?
| | Blotting, Western | 7 | 2012 | 1225 | 0.260 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 4 | 2012 | 114 | 0.260 |
Why?
| | Cell Proliferation | 4 | 2011 | 2472 | 0.260 |
Why?
| | Drug Monitoring | 1 | 2008 | 218 | 0.260 |
Why?
| | Transplant Recipients | 2 | 2018 | 179 | 0.250 |
Why?
| | Nucleotides | 1 | 2007 | 125 | 0.250 |
Why?
| | Disease Progression | 3 | 2022 | 2750 | 0.250 |
Why?
| | Microsomes, Liver | 2 | 2019 | 86 | 0.250 |
Why?
| | Cannabinoid Receptor Agonists | 5 | 2024 | 46 | 0.250 |
Why?
| | Epilepsy | 2 | 2020 | 331 | 0.240 |
Why?
| | Rats, Wistar | 5 | 2012 | 455 | 0.240 |
Why?
| | Caffeine | 1 | 2025 | 68 | 0.230 |
Why?
| | Eicosanoids | 1 | 2025 | 62 | 0.230 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 851 | 0.230 |
Why?
| | Isomerism | 1 | 2024 | 56 | 0.230 |
Why?
| | Adult | 19 | 2025 | 37630 | 0.220 |
Why?
| | Monoacylglycerol Lipases | 1 | 2024 | 5 | 0.220 |
Why?
| | Receptor, Cannabinoid, CB2 | 1 | 2024 | 11 | 0.220 |
Why?
| | Gene Expression Profiling | 1 | 2011 | 1772 | 0.220 |
Why?
| | Isotopes | 1 | 2024 | 33 | 0.220 |
Why?
| | Central Nervous System Stimulants | 1 | 2025 | 161 | 0.210 |
Why?
| | Glycerol | 1 | 2024 | 94 | 0.210 |
Why?
| | Dogs | 1 | 2025 | 411 | 0.210 |
Why?
| | Polysomnography | 1 | 2024 | 183 | 0.210 |
Why?
| | Plant Leaves | 1 | 2024 | 147 | 0.210 |
Why?
| | Magnetic Resonance Spectroscopy | 6 | 2012 | 610 | 0.200 |
Why?
| | Psychomotor Performance | 1 | 2025 | 309 | 0.200 |
Why?
| | Kidney Diseases | 2 | 2017 | 407 | 0.190 |
Why?
| | Double-Blind Method | 5 | 2025 | 1981 | 0.190 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 2 | 2012 | 17 | 0.190 |
Why?
| | Administration, Oral | 3 | 2019 | 813 | 0.190 |
Why?
| | Anti-Inflammatory Agents | 1 | 2025 | 496 | 0.180 |
Why?
| | Kynurenine | 1 | 2022 | 114 | 0.180 |
Why?
| | Endotoxemia | 1 | 2022 | 86 | 0.180 |
Why?
| | Marijuana Use | 2 | 2024 | 203 | 0.180 |
Why?
| | Prostaglandins | 2 | 2019 | 97 | 0.180 |
Why?
| | Birth Weight | 1 | 2024 | 514 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 178 | 0.180 |
Why?
| | TRPP Cation Channels | 1 | 2022 | 84 | 0.180 |
Why?
| | Middle Aged | 13 | 2025 | 33228 | 0.180 |
Why?
| | Mice | 11 | 2025 | 17733 | 0.180 |
Why?
| | Proof of Concept Study | 1 | 2021 | 78 | 0.180 |
Why?
| | Least-Squares Analysis | 2 | 2011 | 79 | 0.170 |
Why?
| | Tryptophan | 1 | 2022 | 183 | 0.170 |
Why?
| | Quality Control | 1 | 2021 | 171 | 0.170 |
Why?
| | Marijuana Abuse | 1 | 2023 | 232 | 0.170 |
Why?
| | Liver Transplantation | 2 | 2018 | 871 | 0.170 |
Why?
| | Sensation Disorders | 1 | 2020 | 37 | 0.170 |
Why?
| | Pravastatin | 2 | 2021 | 41 | 0.160 |
Why?
| | Volatilization | 1 | 2019 | 56 | 0.160 |
Why?
| | Molecular Structure | 2 | 2014 | 489 | 0.160 |
Why?
| | Cytokines | 2 | 2025 | 2083 | 0.160 |
Why?
| | Intralaminar Thalamic Nuclei | 1 | 2019 | 16 | 0.160 |
Why?
| | Isoflurane | 1 | 2019 | 31 | 0.160 |
Why?
| | Myocardium | 2 | 2017 | 1001 | 0.160 |
Why?
| | Nebulizers and Vaporizers | 1 | 2019 | 86 | 0.160 |
Why?
| | Persian Gulf Syndrome | 1 | 2019 | 17 | 0.160 |
Why?
| | Leukotrienes | 1 | 2019 | 37 | 0.150 |
Why?
| | Biological Availability | 2 | 2019 | 148 | 0.150 |
Why?
| | Amino Acids | 2 | 2016 | 497 | 0.150 |
Why?
| | Cross-Over Studies | 3 | 2025 | 562 | 0.150 |
Why?
| | Adenosine | 4 | 2013 | 225 | 0.150 |
Why?
| | Rats, Inbred Lew | 4 | 2012 | 114 | 0.150 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2015 | 443 | 0.150 |
Why?
| | Cognition | 2 | 2023 | 1146 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2020 | 215 | 0.140 |
Why?
| | Sleep | 1 | 2024 | 753 | 0.140 |
Why?
| | Graft Survival | 2 | 2018 | 534 | 0.140 |
Why?
| | Calcium Channels, T-Type | 1 | 2019 | 96 | 0.140 |
Why?
| | Time Factors | 5 | 2022 | 6806 | 0.140 |
Why?
| | Group IV Phospholipases A2 | 1 | 2017 | 47 | 0.140 |
Why?
| | Therapies, Investigational | 1 | 2017 | 17 | 0.140 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.140 |
Why?
| | Pilot Projects | 3 | 2023 | 1692 | 0.140 |
Why?
| | Sex Characteristics | 3 | 2023 | 759 | 0.140 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2017 | 32 | 0.130 |
Why?
| | Endothelium | 2 | 2014 | 122 | 0.130 |
Why?
| | Piperazines | 2 | 2009 | 350 | 0.130 |
Why?
| | Ureteral Obstruction | 1 | 2017 | 64 | 0.130 |
Why?
| | Anesthesia | 1 | 2019 | 189 | 0.130 |
Why?
| | Nuclear Magnetic Resonance, Biomolecular | 2 | 2010 | 340 | 0.130 |
Why?
| | Glycolysis | 4 | 2012 | 319 | 0.130 |
Why?
| | Young Adult | 9 | 2025 | 13129 | 0.130 |
Why?
| | Ischemia | 2 | 2012 | 407 | 0.130 |
Why?
| | Bone Marrow | 1 | 2017 | 286 | 0.130 |
Why?
| | Pyrimidines | 2 | 2009 | 470 | 0.120 |
Why?
| | Air Pollution | 1 | 2019 | 315 | 0.120 |
Why?
| | Sepsis | 1 | 2022 | 614 | 0.120 |
Why?
| | Drug Interactions | 2 | 2025 | 407 | 0.120 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 381 | 0.120 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2015 | 62 | 0.120 |
Why?
| | MAP Kinase Signaling System | 1 | 2017 | 320 | 0.110 |
Why?
| | Brain | 2 | 2025 | 2664 | 0.110 |
Why?
| | Lipoproteins, VLDL | 1 | 2014 | 18 | 0.110 |
Why?
| | Mice, Knockout | 6 | 2019 | 3003 | 0.110 |
Why?
| | Substance-Related Disorders | 1 | 2023 | 1069 | 0.110 |
Why?
| | Protein Kinases | 3 | 2017 | 319 | 0.110 |
Why?
| | Mice, Inbred C57BL | 7 | 2022 | 5735 | 0.110 |
Why?
| | Stearoyl-CoA Desaturase | 1 | 2014 | 65 | 0.110 |
Why?
| | Drug Stability | 2 | 2011 | 167 | 0.110 |
Why?
| | Linoleic Acids, Conjugated | 1 | 2013 | 8 | 0.110 |
Why?
| | 5'-Nucleotidase | 1 | 2013 | 41 | 0.110 |
Why?
| | Receptor, Adenosine A2B | 1 | 2013 | 43 | 0.110 |
Why?
| | Phosphates | 3 | 2012 | 182 | 0.100 |
Why?
| | Child | 7 | 2022 | 21822 | 0.100 |
Why?
| | Regression Analysis | 2 | 2012 | 1022 | 0.100 |
Why?
| | MAP Kinase Kinase Kinase 5 | 1 | 2012 | 6 | 0.100 |
Why?
| | Dinoprost | 3 | 2019 | 44 | 0.100 |
Why?
| | Models, Animal | 2 | 2013 | 384 | 0.100 |
Why?
| | Tissue Distribution | 4 | 2019 | 330 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 36 | 0.100 |
Why?
| | Polycystic Kidney Diseases | 1 | 2013 | 76 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 2012 | 59 | 0.100 |
Why?
| | Principal Component Analysis | 1 | 2012 | 194 | 0.090 |
Why?
| | Cytochrome P-450 Enzyme System | 2 | 2025 | 155 | 0.090 |
Why?
| | Nucleosides | 1 | 2011 | 27 | 0.090 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2012 | 283 | 0.090 |
Why?
| | Transplantation | 1 | 2011 | 34 | 0.090 |
Why?
| | Reference Values | 1 | 2013 | 816 | 0.090 |
Why?
| | Prognosis | 3 | 2018 | 4013 | 0.090 |
Why?
| | PTEN Phosphohydrolase | 1 | 2012 | 162 | 0.090 |
Why?
| | Myocardial Ischemia | 1 | 2012 | 262 | 0.090 |
Why?
| | Prospective Studies | 5 | 2025 | 7572 | 0.090 |
Why?
| | Mutation | 1 | 2022 | 3946 | 0.080 |
Why?
| | Glucose | 3 | 2017 | 1019 | 0.080 |
Why?
| | Cell Cycle | 2 | 2011 | 601 | 0.080 |
Why?
| | Substance Abuse Detection | 2 | 2022 | 87 | 0.080 |
Why?
| | Organ Size | 2 | 2025 | 477 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2011 | 3405 | 0.080 |
Why?
| | Citric Acid Cycle | 1 | 2010 | 57 | 0.080 |
Why?
| | Diabetic Nephropathies | 1 | 2013 | 294 | 0.080 |
Why?
| | Aged | 3 | 2025 | 23794 | 0.080 |
Why?
| | Case-Control Studies | 4 | 2021 | 3540 | 0.080 |
Why?
| | Estrogens | 1 | 2013 | 367 | 0.080 |
Why?
| | Regional Blood Flow | 1 | 2012 | 473 | 0.080 |
Why?
| | High-Throughput Screening Assays | 1 | 2011 | 158 | 0.080 |
Why?
| | Drug Therapy, Combination | 1 | 2012 | 1062 | 0.080 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2012 | 455 | 0.080 |
Why?
| | Prostaglandins A | 1 | 2009 | 10 | 0.080 |
Why?
| | Cardiomyopathy, Dilated | 1 | 2012 | 383 | 0.080 |
Why?
| | Phenotype | 3 | 2022 | 3188 | 0.080 |
Why?
| | Urinalysis | 1 | 2009 | 77 | 0.070 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 121 | 0.070 |
Why?
| | Attention | 2 | 2023 | 426 | 0.070 |
Why?
| | Osmotic Pressure | 1 | 2008 | 37 | 0.070 |
Why?
| | Saline Solution, Hypertonic | 1 | 2008 | 41 | 0.070 |
Why?
| | Disease Models, Animal | 2 | 2022 | 4281 | 0.070 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2122 | 0.070 |
Why?
| | Breast Neoplasms | 2 | 2011 | 2234 | 0.070 |
Why?
| | Calcineurin Inhibitors | 1 | 2008 | 72 | 0.070 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2008 | 150 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2022 | 0.070 |
Why?
| | Pregnancy | 3 | 2025 | 6728 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2023 | 2486 | 0.070 |
Why?
| | Myocytes, Cardiac | 1 | 2011 | 523 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2018 | 2639 | 0.070 |
Why?
| | Cell Survival | 1 | 2010 | 1114 | 0.060 |
Why?
| | Diet | 1 | 2014 | 1274 | 0.060 |
Why?
| | Cell Line | 2 | 2012 | 2837 | 0.060 |
Why?
| | Hydroxylation | 2 | 2019 | 39 | 0.060 |
Why?
| | Organ Preservation Solutions | 1 | 2006 | 45 | 0.060 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2008 | 974 | 0.060 |
Why?
| | Organ Preservation | 1 | 2006 | 102 | 0.060 |
Why?
| | Lipoxygenase | 1 | 2025 | 18 | 0.060 |
Why?
| | Longitudinal Studies | 1 | 2013 | 2829 | 0.060 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2025 | 77 | 0.060 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2009 | 800 | 0.050 |
Why?
| | Stroke | 1 | 2013 | 1118 | 0.050 |
Why?
| | Polymers | 1 | 2008 | 488 | 0.050 |
Why?
| | Adaptation, Physiological | 1 | 2008 | 549 | 0.050 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 809 | 0.050 |
Why?
| | Amygdala | 1 | 2025 | 191 | 0.050 |
Why?
| | Creatinine | 2 | 2022 | 499 | 0.050 |
Why?
| | Infant, Newborn | 2 | 2025 | 6033 | 0.050 |
Why?
| | Asthma | 1 | 2016 | 2282 | 0.050 |
Why?
| | Child, Preschool | 3 | 2024 | 11000 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2005 | 279 | 0.050 |
Why?
| | Aging | 1 | 2013 | 1861 | 0.050 |
Why?
| | Kidney Failure, Chronic | 1 | 2008 | 566 | 0.050 |
Why?
| | TRPV Cation Channels | 1 | 2022 | 40 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2008 | 916 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2024 | 5423 | 0.050 |
Why?
| | Mice, Mutant Strains | 1 | 2022 | 297 | 0.050 |
Why?
| | Harm Reduction | 1 | 2021 | 38 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2024 | 10744 | 0.040 |
Why?
| | Infant | 2 | 2025 | 9398 | 0.040 |
Why?
| | Area Under Curve | 1 | 2021 | 314 | 0.040 |
Why?
| | Breast Feeding | 1 | 2024 | 439 | 0.040 |
Why?
| | Databases, Genetic | 1 | 2022 | 237 | 0.040 |
Why?
| | Massachusetts | 1 | 2021 | 171 | 0.040 |
Why?
| | Adolescent | 5 | 2021 | 21382 | 0.040 |
Why?
| | Interleukin-10 | 1 | 2022 | 302 | 0.040 |
Why?
| | Central Nervous System | 1 | 2022 | 258 | 0.040 |
Why?
| | Verbal Learning | 1 | 2020 | 60 | 0.040 |
Why?
| | Reward | 1 | 2022 | 244 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 464 | 0.040 |
Why?
| | Cytochrome P-450 CYP2C8 | 1 | 2019 | 15 | 0.040 |
Why?
| | Hippocampus | 1 | 2025 | 894 | 0.040 |
Why?
| | 2-Propanol | 1 | 2019 | 20 | 0.040 |
Why?
| | Imatinib Mesylate | 2 | 2009 | 79 | 0.040 |
Why?
| | Gulf War | 1 | 2019 | 15 | 0.040 |
Why?
| | Calibration | 1 | 2019 | 146 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 88 | 0.040 |
Why?
| | Metabolic Clearance Rate | 1 | 2019 | 115 | 0.040 |
Why?
| | Dopamine | 1 | 2022 | 303 | 0.040 |
Why?
| | Half-Life | 1 | 2019 | 164 | 0.040 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2019 | 88 | 0.040 |
Why?
| | Membrane Potentials | 1 | 2019 | 284 | 0.040 |
Why?
| | Benzamides | 2 | 2009 | 216 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2019 | 180 | 0.040 |
Why?
| | Surface Properties | 1 | 2019 | 412 | 0.040 |
Why?
| | Lipopolysaccharides | 1 | 2022 | 886 | 0.040 |
Why?
| | Analgesics | 1 | 2020 | 205 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 327 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2019 | 403 | 0.040 |
Why?
| | Therapeutic Equivalency | 1 | 2017 | 32 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 2022 | 449 | 0.040 |
Why?
| | Bayes Theorem | 1 | 2020 | 404 | 0.040 |
Why?
| | Postural Balance | 1 | 2020 | 216 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2018 | 415 | 0.030 |
Why?
| | Veterans Health | 1 | 2019 | 185 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2021 | 2052 | 0.030 |
Why?
| | Environmental Monitoring | 1 | 2019 | 369 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2017 | 282 | 0.030 |
Why?
| | Malates | 1 | 2016 | 7 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 152 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 185 | 0.030 |
Why?
| | Betaine | 1 | 2016 | 73 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 420 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2375 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 2 | 2025 | 3555 | 0.030 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2015 | 6 | 0.030 |
Why?
| | Linoleic Acids | 1 | 2015 | 7 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 665 | 0.030 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2015 | 43 | 0.030 |
Why?
| | Executive Function | 1 | 2020 | 440 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2017 | 810 | 0.030 |
Why?
| | Retrospective Studies | 1 | 2013 | 15504 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 551 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 640 | 0.030 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2013 | 18 | 0.030 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2013 | 23 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 2060 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2412 | 0.030 |
Why?
| | bcl-2-Associated X Protein | 1 | 2013 | 56 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 382 | 0.030 |
Why?
| | Protein Deglycase DJ-1 | 1 | 2012 | 11 | 0.020 |
Why?
| | Infarction, Middle Cerebral Artery | 1 | 2013 | 40 | 0.020 |
Why?
| | Ion Transport | 1 | 2012 | 60 | 0.020 |
Why?
| | Body Composition | 1 | 2016 | 679 | 0.020 |
Why?
| | Gluconeogenesis | 1 | 2012 | 79 | 0.020 |
Why?
| | Nucleoside Transport Proteins | 1 | 2012 | 7 | 0.020 |
Why?
| | No-Reflow Phenomenon | 1 | 2012 | 7 | 0.020 |
Why?
| | Dipyridamole | 1 | 2012 | 28 | 0.020 |
Why?
| | Receptors, Purinergic P1 | 1 | 2012 | 26 | 0.020 |
Why?
| | Chimerism | 1 | 2012 | 31 | 0.020 |
Why?
| | Smoking | 1 | 2020 | 1620 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2792 | 0.020 |
Why?
| | Overweight | 1 | 2016 | 557 | 0.020 |
Why?
| | Neuroprotective Agents | 1 | 2013 | 131 | 0.020 |
Why?
| | Inosine | 1 | 2011 | 14 | 0.020 |
Why?
| | Receptors, Purinergic | 1 | 2011 | 22 | 0.020 |
Why?
| | Phosphodiesterase Inhibitors | 1 | 2012 | 89 | 0.020 |
Why?
| | Scutellaria | 1 | 2011 | 3 | 0.020 |
Why?
| | Scutellaria baicalensis | 1 | 2011 | 4 | 0.020 |
Why?
| | Cytoskeleton | 1 | 2012 | 188 | 0.020 |
Why?
| | Solid Phase Extraction | 1 | 2011 | 25 | 0.020 |
Why?
| | Colorado | 1 | 2021 | 4518 | 0.020 |
Why?
| | Drug-Eluting Stents | 1 | 2011 | 81 | 0.020 |
Why?
| | Methylation | 1 | 2011 | 230 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 267 | 0.020 |
Why?
| | Cyclic AMP | 1 | 2011 | 234 | 0.020 |
Why?
| | Cell Hypoxia | 1 | 2011 | 226 | 0.020 |
Why?
| | Cohort Studies | 1 | 2021 | 5701 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 372 | 0.020 |
Why?
| | Gene Deletion | 1 | 2011 | 389 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 89 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 372 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5106 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1321 | 0.020 |
Why?
| | Reference Standards | 1 | 2009 | 186 | 0.020 |
Why?
| | Nitric Oxide | 1 | 2014 | 915 | 0.020 |
Why?
| | Phosphorylation | 1 | 2012 | 1758 | 0.020 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2013 | 858 | 0.020 |
Why?
| | Phospholipids | 1 | 2009 | 222 | 0.020 |
Why?
| | Lactic Acid | 1 | 2009 | 305 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2011 | 512 | 0.020 |
Why?
| | Procaine | 1 | 2006 | 4 | 0.020 |
Why?
| | Raffinose | 1 | 2006 | 23 | 0.020 |
Why?
| | F2-Isoprostanes | 1 | 2006 | 21 | 0.020 |
Why?
| | Potassium Chloride | 1 | 2006 | 38 | 0.020 |
Why?
| | Mannitol | 1 | 2006 | 38 | 0.020 |
Why?
| | Allopurinol | 1 | 2006 | 63 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2006 | 124 | 0.020 |
Why?
| | Creatine | 1 | 2006 | 57 | 0.020 |
Why?
| | Cold Ischemia | 1 | 2006 | 30 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1935 | 0.020 |
Why?
| | Kidney Function Tests | 1 | 2006 | 159 | 0.020 |
Why?
| | Genotype | 1 | 2011 | 1914 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2009 | 1177 | 0.010 |
Why?
| | Allantoin | 1 | 2005 | 2 | 0.010 |
Why?
| | Perfusion | 1 | 2006 | 211 | 0.010 |
Why?
| | Methylamines | 1 | 2005 | 34 | 0.010 |
Why?
| | Fatty Acids, Unsaturated | 1 | 2005 | 98 | 0.010 |
Why?
| | Glutathione | 1 | 2006 | 356 | 0.010 |
Why?
| | Risk Factors | 1 | 2018 | 10326 | 0.010 |
Why?
| | Uric Acid | 1 | 2005 | 163 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 4190 | 0.010 |
Why?
| | Mitochondria, Liver | 1 | 2003 | 73 | 0.010 |
Why?
| | Mitochondria, Heart | 1 | 2003 | 100 | 0.010 |
Why?
| | Organ Specificity | 1 | 2003 | 304 | 0.010 |
Why?
| | Reactive Oxygen Species | 1 | 2005 | 621 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2605 | 0.010 |
Why?
| | United States | 1 | 2018 | 14691 | 0.010 |
Why?
| | Apoptosis | 1 | 2009 | 2551 | 0.010 |
Why?
| | Insulin | 1 | 2006 | 2406 | 0.010 |
Why?
|
|
Klawitter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|